Market Cap 61.84M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.82
Volume 802,700
Avg Vol 386,964
Day's Range N/A - N/A
Shares Out 45.47M
Stochastic %K 70%
Beta 0.80
Analysts Strong Sell
Price Target $8.00

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
PaulLaurent
PaulLaurent Jun. 19 at 8:50 PM
πŸ“ˆ 4:00am EST Watchlist – June 19 $GRRR – Gorilla Technology posted a strong Q1 2025 with revenue up 109% YoY to $18.3M. Adjusted EBITDA reached $5.2M and net income came in at $4.5M vs. a $9M loss last year. The company reported a $33.8M cash balance, reduced debt to $18.4M, and highlighted a deal pipeline over $5B. $QNCX – Quince Therapeutics secured a $22M private placement led by Nantahala Capital. The raise includes $11.5M upfront and additional funds via warrants, supporting Phase 3 NEAT trial for Ataxia-Telangiectasia and extending cash runway into Q2 2026. $GNS – No new filings, but $GNS continues to trade with high retail momentum and speculation. Often discussed for its anti-manipulation stance and history of retail-driven volatility. $NINE – Oil sector still in play. Nine Energy remains a potential multi-day runner amid broader energy sector strength. $SAFX – Another candidate from the Oil Hive, SAFX draws interest as traders watch for continuation plays.
1 Β· Reply
SearchFor911
SearchFor911 Jun. 19 at 3:20 AM
$QNCX And here we are. Unfortunately there was no update regarding screened patients but I would now assume nearly full enrollment until end of June.
0 Β· Reply
ADSlay
ADSlay Jun. 18 at 8:45 PM
$QNCX "This transaction reflects a significant commitment from high caliber healthcare investors who believe in our technology platform and Phase 3 asset, eDSP." -- this is the money quote πŸš€πŸš€πŸš€ I dunno what else to say. Next PR should be 100% enrollment completion and then clock starts for trial completion in 6 months.
0 Β· Reply
ADSlay
ADSlay Jun. 18 at 8:20 PM
$QNCX Total enrolled = 95 6-9y enrolled = 77 > 10y = 18 They need 11 more! With the way they're going, we will be done by end of this month!?? πŸš€πŸš€πŸš€ Brilliant progress!
1 Β· Reply
boncuk
boncuk Jun. 18 at 8:14 PM
$QNCX QNCX Borrow Fee (CTB) Latest As of 2025-06-18 04:01:48 PM EDT, there were 500,000 shares available with a fee of 5.56%.
0 Β· Reply
patb99
patb99 Jun. 18 at 8:12 PM
$QNCX 🧐
0 Β· Reply
SearchFor911
SearchFor911 Jun. 18 at 8:09 PM
$QNCX A total of 95 participants have been enrolled, including 77 participants in the six to nine year-old primary analysis population and 18 participants aged 10 years or older. All 39 NEAT participants to date have elected to transition to the NEAT open label extension
0 Β· Reply
RunningRobert1
RunningRobert1 Jun. 16 at 2:51 PM
$QNCX Quince Therapeutics QNCX Private Placement Summary 16Jun2025 https://youtu.be/1Gu_urbUy3w An overall summary of the company, the data thats coming, and the private placement. Overall we are in good shape to see that run up to data early next year!
0 Β· Reply
StockScanners
StockScanners Jun. 14 at 4:03 PM
$QNCX Keep watch if this holds above 1.25
0 Β· Reply
Ice_Wizard
Ice_Wizard Jun. 13 at 10:37 PM
$QNCX entered into a PIPE agreement today so looking for a channel breakout continuation for that resale filing
0 Β· Reply
Latest News on QNCX
Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board


Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.


Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.


Quince Therapeutics to Present at Upcoming Scientific Meetings

Aug 25, 2022, 4:05 PM EDT - 3 years ago

Quince Therapeutics to Present at Upcoming Scientific Meetings


PaulLaurent
PaulLaurent Jun. 19 at 8:50 PM
πŸ“ˆ 4:00am EST Watchlist – June 19 $GRRR – Gorilla Technology posted a strong Q1 2025 with revenue up 109% YoY to $18.3M. Adjusted EBITDA reached $5.2M and net income came in at $4.5M vs. a $9M loss last year. The company reported a $33.8M cash balance, reduced debt to $18.4M, and highlighted a deal pipeline over $5B. $QNCX – Quince Therapeutics secured a $22M private placement led by Nantahala Capital. The raise includes $11.5M upfront and additional funds via warrants, supporting Phase 3 NEAT trial for Ataxia-Telangiectasia and extending cash runway into Q2 2026. $GNS – No new filings, but $GNS continues to trade with high retail momentum and speculation. Often discussed for its anti-manipulation stance and history of retail-driven volatility. $NINE – Oil sector still in play. Nine Energy remains a potential multi-day runner amid broader energy sector strength. $SAFX – Another candidate from the Oil Hive, SAFX draws interest as traders watch for continuation plays.
1 Β· Reply
SearchFor911
SearchFor911 Jun. 19 at 3:20 AM
$QNCX And here we are. Unfortunately there was no update regarding screened patients but I would now assume nearly full enrollment until end of June.
0 Β· Reply
ADSlay
ADSlay Jun. 18 at 8:45 PM
$QNCX "This transaction reflects a significant commitment from high caliber healthcare investors who believe in our technology platform and Phase 3 asset, eDSP." -- this is the money quote πŸš€πŸš€πŸš€ I dunno what else to say. Next PR should be 100% enrollment completion and then clock starts for trial completion in 6 months.
0 Β· Reply
ADSlay
ADSlay Jun. 18 at 8:20 PM
$QNCX Total enrolled = 95 6-9y enrolled = 77 > 10y = 18 They need 11 more! With the way they're going, we will be done by end of this month!?? πŸš€πŸš€πŸš€ Brilliant progress!
1 Β· Reply
boncuk
boncuk Jun. 18 at 8:14 PM
$QNCX QNCX Borrow Fee (CTB) Latest As of 2025-06-18 04:01:48 PM EDT, there were 500,000 shares available with a fee of 5.56%.
0 Β· Reply
patb99
patb99 Jun. 18 at 8:12 PM
$QNCX 🧐
0 Β· Reply
SearchFor911
SearchFor911 Jun. 18 at 8:09 PM
$QNCX A total of 95 participants have been enrolled, including 77 participants in the six to nine year-old primary analysis population and 18 participants aged 10 years or older. All 39 NEAT participants to date have elected to transition to the NEAT open label extension
0 Β· Reply
RunningRobert1
RunningRobert1 Jun. 16 at 2:51 PM
$QNCX Quince Therapeutics QNCX Private Placement Summary 16Jun2025 https://youtu.be/1Gu_urbUy3w An overall summary of the company, the data thats coming, and the private placement. Overall we are in good shape to see that run up to data early next year!
0 Β· Reply
StockScanners
StockScanners Jun. 14 at 4:03 PM
$QNCX Keep watch if this holds above 1.25
0 Β· Reply
Ice_Wizard
Ice_Wizard Jun. 13 at 10:37 PM
$QNCX entered into a PIPE agreement today so looking for a channel breakout continuation for that resale filing
0 Β· Reply
iAm_Goatz
iAm_Goatz Jun. 13 at 10:09 PM
$QNCX is getting some interest on X if y'all wanna support your investment 🫑 https://x.com/iam_goatz/status/1933647150375645602?s=46
0 Β· Reply
pbacher
pbacher Jun. 13 at 6:23 PM
$QNCX nice recovery so far
0 Β· Reply
ADSlay
ADSlay Jun. 13 at 5:18 PM
$QNCX Before screaming dilution: - Did you even research who are these guys? - Did you even ask yourself why they agreed to Quince when there were hundreds of other options? - Did you notice Quince Senior Management is also in it? - Have you run a business?
0 Β· Reply
RD008
RD008 Jun. 13 at 4:32 PM
$QNCX https://www.investing.com/news/analyst-ratings/quince-therapeutics-stock-target-cut-to-4-from-12-maintains-buy-93CH-3946950
0 Β· Reply
ADSlay
ADSlay Jun. 13 at 4:11 PM
$QNCX People scream dilution dilution. Understandable. Biotech is a scammy sector. Scammiest, actually. But we all know running trials is expensive. I had said to myself, if Quince eDSP is legit, someone may step in to finance us. Had thought about it even if fleetingly. And see who all stepped in! This is LEGIT biotech monies! It doesn't get better than this. Look up their history. If they have invested with us, it is not short of a miracle or eDSP works! What biotech sector has gone through past four years and still be here to get financial support like this, make what you will but our thesis here just got wings.
0 Β· Reply
JarvisFlow
JarvisFlow Jun. 13 at 12:00 PM
D. Boral Capital updates rating for Quince Therapeutics ( $QNCX ) to Buy, target set at 4.
0 Β· Reply
SearchFor911
SearchFor911 Jun. 13 at 4:27 AM
$QNCX i guess it was the financing in preparation mode. Warrrants at 1,20$ πŸ˜…
1 Β· Reply
rfcacal
rfcacal Jun. 12 at 11:10 PM
$QNCX curling back up?
0 Β· Reply
pbacher
pbacher Jun. 12 at 10:00 PM
$QNCX what did i miss? Every crap stock pumped hard on no news. Here is a nice private placement and we drop faster as i can react =D
1 Β· Reply
Profitrip
Profitrip Jun. 12 at 9:55 PM
0 Β· Reply
ADSlay
ADSlay Jun. 12 at 9:52 PM
$QNCX Impressed with the lining up of who's who of biotech world. When legit biotech companies like us do private placement or raise, it is bullish. But y'all so scarred by scammy biotech companies, lol, go away, we don't care. Go cut your sarcasm elsewhere. We've been in this since '19, lol. Not for kids.
1 Β· Reply
doodledo77
doodledo77 Jun. 12 at 9:41 PM
$QNCX was out so quick... But anyway soon expect a huge pump some of you know why πŸ˜πŸ˜‰.... easy money...if you know how the crooks play πŸ‘πŸ‘πŸ‘πŸ‘πŸ˜‚πŸ€£πŸ˜‚πŸ˜
0 Β· Reply